Compile Data Set for Download or QSAR
Report error Found 170 Enz. Inhib. hit(s) with all data for entry = 10037
TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510048(WO2021250648, Example 1 | (1R,2S,5S)-N-{(1S)-1-Cya...)
Affinity DataEC50:  246nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510050(WO2021250648, Example 2 | N-{(1S)-1-Cyano-2-[(3S)-...)
Affinity DataEC50:  7.52E+3nMAssay Description:The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510051(WO2021250648, Example 3 | N-{(1S)-1-Cyano-2-[(3S)-...)
Affinity DataEC50:  6.74E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM496896(science.abl4784, 2 | WO2021250648, Example 4 | US1...)
Affinity DataEC50:  1.36E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510053(WO2021250648, Example 5 | N-[(2S)-1-({(1S)-1-Cyano...)
Affinity DataEC50: >3.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510054(WO2021250648, Example 6 | N-[(2S)-1-({(1S)-1-Cyano...)
Affinity DataEC50:  279nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510055(WO2021250648, Example 7 | N-[(2S)-1-({(1 S)-1-Cyan...)
Affinity DataEC50:  4.31E+4nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510056(WO2021250648, Example 8 | N-{1-Cyano-2-[(3S)-2-oxo...)
Affinity DataEC50:  5.75E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510057(WO2021250648, Example 9 | N-{1-Cyano-2-[(3S)-2-oxo...)
Affinity DataEC50:  970nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509871(US11124497, Compound 405 | US11524940, Compound 40...)
Affinity DataEC50:  2.09E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510059(WO2021250648, Example 11 | N2-[(4-Bromo-1-ethyl-3-...)
Affinity DataEC50:  4.78E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510060(WO2021250648, Example 12 | N-{(1 S)-1-Cyano-2-[(3S...)
Affinity DataEC50:  6.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM496902(PF-07321332 | science.abl4784, 6 | WO2021250648, E...)
Affinity DataEC50:  75nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510063(WO2021250648, Example 15 | N-[(2S)-1-({(1S)-1-Cyan...)
Affinity DataEC50:  360nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510064(WO2021250648, Example 16 | N-[(2S)-1-({(1S)-1- Cya...)
Affinity DataEC50: >2.53E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510065(WO2021250648, Example 17 | N-[(2S)-1-({(1S)-1-Cyan...)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510066(WO2021250648, Example 18 | N-[(2S)-1-({(1S)-1-Cyan...)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510067(WO2021250648, Example 19 | N-[(2S)-1-({(1 S)-1-Cya...)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510068(WO2021250648, Example 20 | N-[(2S)-1-({(1 S)-1-Cya...)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510070(WO2021250648, Example 22 | N-[(2S)-1-({(1 S)-1-Cya...)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510071(WO2021250648, Example 23 | N-[(2S)-1-({(1S)-1-Cyan...)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510072(WO2021250648, Example 24 | US11351149, Example 24)
Affinity DataEC50:  6.30E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510073(WO2021250648, Example 25)
Affinity DataEC50:  3.70E+4nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510074(WO2021250648, Example 26)
Affinity DataEC50: >1.00E+5nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510075(WO2021250648, Example 27 | US11351149, Example 27)
Affinity DataEC50:  4.49E+4nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510076(WO2021250648, Example 28 | US11351149, Example 28)
Affinity DataEC50:  7.26E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510077(WO2021250648, Example 29 | US11351149, Example 29)
Affinity DataEC50:  2.81E+4nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510078(WO2021250648, Example 30 | US11351149, Example 30)
Affinity DataEC50:  9.37E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510079(WO2021250648, Example 31)
Affinity DataEC50:  4.07E+4nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510080(WO2021250648, Example 32)
Affinity DataEC50:  4.90E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510081(WO2021250648, Example 33 | US11351149, Example 33)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510082(WO2021250648, Example 34 | US11351149, Example 34)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510083(WO2021250648, Example 35 | US11351149, Example 35)
Affinity DataEC50:  3.56E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510084(WO2021250648, Example 36 | US11351149, Example 36)
Affinity DataEC50:  1.03E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510085(WO2021250648, Example 37 | US11351149, Example 37)
Affinity DataEC50: >3.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510086(WO2021250648, Example 38 | US11351149, Example 38)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510087(WO2021250648, Example 39 | US11351149, Example 39)
Affinity DataEC50: >3.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510088(WO2021250648, Example 40 | US11351149, Example 40)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510089(WO2021250648, Example 41 | US11351149, Example 41)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510090(WO2021250648, Example 42 | US11351149, Example 42)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510091(WO2021250648, Example 43 | US11351149, Example 43)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510092(WO2021250648, Example 44 | US11351149, Example 44)
Affinity DataEC50: >333nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510093(WO2021250648, Example 45 | US11351149, Example 45)
Affinity DataEC50:  6.42E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510094(WO2021250648, Example 46 | US11351149, Example 46)
Affinity DataEC50: >3.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510095(WO2021250648, Example 47 | US11351149, Example 47)
Affinity DataEC50: >3.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510096(WO2021250648, Example 48 | US11351149, Example 48)
Affinity DataEC50: >3.33E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509848(US11124497, Compound 361 | US11524940, Compound 36...)
Affinity DataEC50:  2.68E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510098(WO2021250648, Example 50)
Affinity DataEC50:  3.95E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510117(WO2021250648, Example 69 | US11351149, Example 69)
Affinity DataEC50: >2.67E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM510118(WO2021250648, Example 70 | US11351149, Example 70)
Affinity DataEC50:  4.09E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
WIPO WO2021250648

Displayed 1 to 50 (of 170 total ) | Next | Last >>
Jump to: